제품 > 항체 > Biosimilar Antibody

Human CD19 Monoclonal Antibody (N297Q) (YR0502)

Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD19 (Research Grade Loncastuximab(N297Q) Biosimilar) Monoclonal Antibody to CD19.The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.

Human CD19 SPR assay. Determined through SPR assay, the Human Anti-Human CD19 (Research Grade Loncastuximab (N297Q) Biosimilar) Monoclonal Antibody is Capable of binding to Human CD19 with an affinity constant of 1.288nM.

Basic Information

Clone	Loncastuximab Biosimilar
Molecular Weight	150 kDa
Endotoxin	<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Sterility	0.2 μm filtration
Aggregation	<5% Determined by SECP
Purity	>95% Determined by SDS-PAGE

Product Information

Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A or G purification
Storage	2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Target Background

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).